 | |
| Clinical data | |
|---|---|
| Trade names | Moizerto, Adquey |
| Other names | OPA-15406 |
| License data | |
| Routes of administration | Topical |
| Drug class | PDE4 inhibitor,dermatologic agent |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C23H24F2N2O5 |
| Molar mass | 446.451 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Difamilast, sold under the brand nameMoizerto among others, is amedication used for the treatment ofatopic dermatitis.[1] Difamilast is non-steroidal topicalphosphodiesterase 4 (PDE4) inhibitor.[1] Difamilast was discovered and developed byOtsuka Pharmaceutical.[2][3][4][5]
Difamilast was approved for medical use in Japan in September 2021,[2] and in the United States in February 2026.[3][6]
Difamilast isindicated for the topical treatment people with mild to moderateatopic dermatitis.[1]
Difamilast was approved for medical use in Japan in September 2021,[2] and in the United States in February 2026.[3]
Difamilast is theinternational nonproprietary name.[7]
Difamilast is sold under the brand names Moizerto (JP)[2] and Adquey (US).[3]
 | Thispharmacology-related article is astub. You can help Wikipedia byadding missing information. |
